{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:59:32Z","timestamp":1787270372189,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypoalbuminemia is common in critically ill patients, yet albumin replacement remains controversial. Beyond volume regulation, albumin transports sphingosine\u00a01-phosphate (S1P), a key modulator of immunity and endothelial stability. This study investigates how human albumin (HA) affects S1P distribution between high-density lipoprotein (HDL-cholesterol, HDL) and serum albumin (SA) and its impact on lymphocyte migration and vascular integrity ex\u00a0vivo. Between March 2022 and February 2023, a prospective observational cohort study (AlbuS1P Study) was conducted in an intensive care unit (ICU). A total of 47 patients were enrolled and stratified based on baseline SA levels: Group A (normal SA, untreated control), Group B (low SA, untreated control) and Group C (low SA, treated with 180\u00a0g HA over three days). Blood samples were collected at multiple time points for laboratory analyses, including S1P quantification, immune cell assessments, ApoM ELISA and flow-induced dispersion analysis (FIDA) to determine S1P binding to SA or HDL. In this cohort study of 42 ICU patients with hypoalbuminemia, HA administration increased SA-levels (+\u20090.7\u00a0g\/dL, +\u200940%) but had no effect on free plasma S1P levels. HA treatment tended to shift S1P binding from HDL to SA in vivo and coincided with lower CD4\u207a T cell and CD19\u207a B cell counts, a finding that could be consistent with, but does not prove, reduced S1P-driven immune cell migration. In contrast, ex vivo assays showed no significant effects of HA-treated plasma on endothelial barrier function or S1P-mediated lymphocyte chemotaxis. These findings are consistent with the notion that HA treatment may modulate S1P distribution in vivo in patients, potentially influencing immune cell dynamics without evidence of impaired vascular stability. HA redistributed S1P from HDL to SA without altering total plasma S1P levels. This shift may correlate with immune modulation and had no negative effect on endothelial stability or cell migration ex vivo. Future studies should identify patient endotypes and subgroups, such as those with low HDL or hyperinflammation, who may benefit from HA\u2019s immunomodulatory effects.<\/jats:p>","DOI":"10.1038\/s41598-026-38157-8","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:05:12Z","timestamp":1770401112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The potential effect of albumin replacement on immune modulation and sphingosine\u00a01-phosphate dynamics"],"prefix":"10.1038","volume":"16","author":[{"given":"M. S.","family":"Winkler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Enzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Seidita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Moerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H.","family":"Gr\u00e4ler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"4","key":"38157_CR1","first-page":"872","volume":"64","author":"F Bernard","year":"2008","unstructured":"Bernard, F. et al. Serum albumin level as a predictor of outcome in traumatic brain injury: potential for treatment. J. Trauma. 64 (4), 872\u2013875 (2008).","journal-title":"J. Trauma."},{"issue":"1","key":"38157_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2009.10.010","volume":"21","author":"O Lyons","year":"2010","unstructured":"Lyons, O., Whelan, B., Bennett, K., O\u2019Riordan, D. & Silke, B. Serum albumin as an outcome predictor in hospital emergency medical admissions. Eur. J. Intern. Med. 21 (1), 17\u201320 (2010).","journal-title":"Eur. J. Intern. Med."},{"issue":"5","key":"38157_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.amjsurg.2016.11.023","volume":"214","author":"CP Meyer","year":"2017","unstructured":"Meyer, C. P. et al. The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures. Am. J. Surg. 214 (5), 871\u2013883 (2017).","journal-title":"Am. J. Surg."},{"issue":"3","key":"38157_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1099800419827600","volume":"21","author":"H Kendall","year":"2019","unstructured":"Kendall, H., Abreu, E. & Cheng, A. L. Serum albumin trend is a predictor of mortality in ICU patients with sepsis. Biol. Res. Nurs. 21 (3), 237\u2013244 (2019).","journal-title":"Biol. Res. Nurs."},{"key":"38157_CR5","doi-asserted-by":"crossref","unstructured":"Albumin, R. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst. Rev. 2011 (10), CD001208.","DOI":"10.1002\/14651858.CD001208.pub4"},{"issue":"2","key":"38157_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/CCM.0b013e3181ffe217","volume":"39","author":"AP Delaney","year":"2011","unstructured":"Delaney, A. P., Dan, A., McCaffrey, J. & Finfer, S. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit. Care Med. 39 (2), 386\u2013391 (2011).","journal-title":"Crit. Care Med."},{"issue":"4","key":"38157_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1042\/cs0950459","volume":"95","author":"GJ Quinlan","year":"1998","unstructured":"Quinlan, G. J., Margarson, M. P., Mumby, S., Evans, T. W. & Gutteridge, J. M. Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion. Clin. Sci. (Lond). 95 (4), 459\u2013465 (1998).","journal-title":"Clin. Sci. (Lond)"},{"issue":"22","key":"38157_CR8","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa040232","volume":"350","author":"S Finfer","year":"2004","unstructured":"Finfer, S. et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl. J. Med. 350 (22), 2247\u20132256 (2004).","journal-title":"N Engl. J. Med."},{"issue":"15","key":"38157_CR9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa1305727","volume":"370","author":"P Caironi","year":"2014","unstructured":"Caironi, P. et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl. J. Med. 370 (15), 1412\u20131421 (2014).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"38157_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1056\/NEJMc1405675","volume":"371","author":"CJ Wiedermann","year":"2014","unstructured":"Wiedermann, C. J. & Joannidis, M. Albumin replacement in severe sepsis or septic shock. N Engl. J. Med. 371 (1), 83 (2014).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"38157_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13054-018-2169-8","volume":"22","author":"F Vasques","year":"2018","unstructured":"Vasques, F. et al. Septic shock-3 vs 2: an analysis of the ALBIOS study. Crit. Care. 22 (1), 237 (2018).","journal-title":"Crit. Care"},{"issue":"11","key":"38157_CR12","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans, L. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit. Care Med. 49 (11), e1063\u2013e1143 (2021).","journal-title":"Crit. Care Med."},{"issue":"7","key":"38157_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3949\/ccjm.91a.23089","volume":"91","author":"R Dunn","year":"2024","unstructured":"Dunn, R., Ham, K., Marks, L. & Agrwal, N. Do patients with sepsis benefit from intravenous albumin? Cleve Clin. J. Med. 91 (7), 405\u2013407 (2024).","journal-title":"Cleve Clin. J. Med."},{"issue":"1","key":"38157_CR14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1056\/NEJMc1405198","volume":"371","author":"P Caironi","year":"2014","unstructured":"Caironi, P., Tognoni, G. & Gattinoni, L. Albumin replacement in severe sepsis or septic shock. N Engl. J. Med. 371 (1), 84 (2014).","journal-title":"N Engl. J. Med."},{"issue":"10","key":"38157_CR15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1097\/CCM.0000000000006348","volume":"52","author":"AJ Gray","year":"2024","unstructured":"Gray, A. J. et al. Albumin versus balanced crystalloid for the early resuscitation of sepsis: an open Parallel-Group randomized feasibility trial- the ABC-Sepsis trial. Crit. Care Med. 52 (10), 1520\u20131532 (2024).","journal-title":"Crit. Care Med."},{"issue":"8","key":"38157_CR16","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/aas.14280","volume":"67","author":"TS Meyhoff","year":"2023","unstructured":"Meyhoff, T. S. et al. Albumin administration in septic shock-Protocol for post-hoc analyses of data from a multicentre RCT. Acta Anaesthesiol. Scand. 67 (8), 1128\u20131136 (2023).","journal-title":"Acta Anaesthesiol. Scand."},{"issue":"6","key":"38157_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/hep.20720","volume":"41","author":"GJ Quinlan","year":"2005","unstructured":"Quinlan, G. J., Martin, G. S. & Evans, T. W. Albumin: biochemical properties and therapeutic potential. Hepatology 41 (6), 1211\u20131219 (2005).","journal-title":"Hepatology"},{"issue":"2","key":"38157_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17512433.2018.1412827","volume":"11","author":"R Ferrer","year":"2018","unstructured":"Ferrer, R. et al. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients. Expert Rev. Clin. Pharmacol. 11 (2), 125\u2013137 (2018).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"4","key":"38157_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(23)00330-2","volume":"12","author":"S Cajander","year":"2024","unstructured":"Cajander, S. et al. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine. Lancet Respir Med. 12 (4), 305\u2013322 (2024).","journal-title":"Lancet Respir Med."},{"issue":"1","key":"38157_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13054-015-1089-0","volume":"19","author":"MS Winkler","year":"2015","unstructured":"Winkler, M. S. et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Crit. Care. 19 (1), 372 (2015).","journal-title":"Crit. Care"},{"issue":"5822","key":"38157_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1139221","volume":"316","author":"R Pappu","year":"2007","unstructured":"Pappu, R. et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316 (5822), 295\u2013298 (2007).","journal-title":"Science"},{"key":"38157_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-immunol-020711-075011","volume":"30","author":"JG Cyster","year":"2012","unstructured":"Cyster, J. G. & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30, 69\u201394 (2012).","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"38157_CR23","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1164\/rccm.200405-684OC","volume":"170","author":"BJ McVerry","year":"2004","unstructured":"McVerry, B. J. et al. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am. J. Respir Crit. Care Med. 170 (9), 987\u2013993 (2004).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"38157_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fphar.2015.00243","volume":"6","author":"B Levkau","year":"2015","unstructured":"Levkau, B. HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front. Pharmacol. 6, 243 (2015).","journal-title":"Front. Pharmacol."},{"key":"38157_CR25","doi-asserted-by":"crossref","unstructured":"Seidita, I. et al. Rapid determination of sphingosine 1-phosphate association with carrier molecules by flow-induced dispersion analysis to predict sepsis outcome. iScience 27 (11), 111168. (2024).","DOI":"10.1016\/j.isci.2024.111168"},{"issue":"824","key":"38157_CR26","doi-asserted-by":"publisher","first-page":"eadg9256","DOI":"10.1126\/scisignal.adg9256","volume":"17","author":"YC Lin","year":"2024","unstructured":"Lin, Y. C. et al. Designer high-density lipoprotein particles enhance endothelial barrier function and suppress inflammation. Sci. Signal. 17 (824), eadg9256 (2024).","journal-title":"Sci. Signal."},{"issue":"11","key":"38157_CR27","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1194\/jlr.R700011-JLR200","volume":"48","author":"KM Argraves","year":"2007","unstructured":"Argraves, K. M. & Argraves, W. S. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J. Lipid Res. 48 (11), 2325\u20132333 (2007).","journal-title":"J. Lipid Res."},{"issue":"1","key":"38157_CR28","doi-asserted-by":"publisher","first-page":"e13424","DOI":"10.15252\/emmm.202013424","volume":"13","author":"G Marfia","year":"2021","unstructured":"Marfia, G. et al. Decreased serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-19. EMBO Mol. Med. 13 (1), e13424 (2021).","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"38157_CR29","doi-asserted-by":"publisher","first-page":"e0216963","DOI":"10.1371\/journal.pone.0216963","volume":"14","author":"SC Hsu","year":"2019","unstructured":"Hsu, S. C. et al. Circulating sphingosine-1-phosphate as a prognostic biomarker for community-acquired pneumonia. PLoS One. 14 (5), e0216963 (2019).","journal-title":"PLoS One"},{"key":"38157_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40560-019-0376-2","volume":"7","author":"MS Winkler","year":"2019","unstructured":"Winkler, M. S. et al. Loss of sphingosine 1-phosphate (S1P) in septic shock is predominantly caused by decreased levels of high-density lipoproteins (HDL). J. Intensive Care. 7, 23 (2019).","journal-title":"J. Intensive Care"},{"key":"38157_CR31","doi-asserted-by":"crossref","unstructured":"Winkler, M. S. et al. Sphingosine-1-phosphate: A potential biomarker and therapeutic target for endothelial dysfunction and sepsis? Shock 47 (6), 666\u2013672. (2017).","DOI":"10.1097\/SHK.0000000000000814"},{"issue":"6","key":"38157_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1097\/SHK.0000000000001229","volume":"51","author":"X Wu","year":"2019","unstructured":"Wu, X. et al. Inverse correlation between plasma Sphingosine-1-Phosphate and ceramide concentrations in septic patients and their utility in predicting mortality. Shock 51 (6), 718\u2013724 (2019).","journal-title":"Shock"},{"issue":"7","key":"38157_CR33","doi-asserted-by":"publisher","first-page":"H1011","DOI":"10.1152\/ajpheart.00829.2013","volume":"306","author":"RH Adamson","year":"2014","unstructured":"Adamson, R. H. et al. Albumin modulates S1P delivery from red blood cells in perfused microvessels: mechanism of the protein effect. Am. J. Physiol. Heart Circ. Physiol. 306 (7), H1011\u20131017 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"53","key":"38157_CR34","doi-asserted-by":"publisher","first-page":"44645","DOI":"10.1074\/jbc.M112.423426","volume":"287","author":"BA Wilkerson","year":"2012","unstructured":"Wilkerson, B. A., Grass, G. D., Wing, S. B., Argraves, W. S. & Argraves, K. M. Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J. Biol. Chem. 287 (53), 44645\u201344653 (2012).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"38157_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13054-021-03545-1","volume":"25","author":"A Piotti","year":"2021","unstructured":"Piotti, A. et al. Endothelial damage in septic shock patients as evidenced by Circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS. Crit. Care. 25 (1), 113 (2021).","journal-title":"Crit. Care"},{"issue":"1","key":"38157_CR36","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1038\/s41598-018-23300-x","volume":"8","author":"N Kobayashi","year":"2018","unstructured":"Kobayashi, N. et al. MFSD2B is a sphingosine 1-phosphate transporter in erythroid cells. Sci. Rep. 8 (1), 4969 (2018).","journal-title":"Sci. Rep."},{"issue":"12","key":"38157_CR37","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/jbmr.3844","volume":"34","author":"A El Jamal","year":"2019","unstructured":"El Jamal, A. et al. Cytokine-Induced and Stretch-Induced sphingosine 1-Phosphate production by enthesis cells could favor abnormal ossification in spondyloarthritis. J. Bone Min. Res. 34 (12), 2264\u20132276 (2019).","journal-title":"J. Bone Min. Res."},{"issue":"3","key":"38157_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jb\/mvad037","volume":"174","author":"K Kiyozuka","year":"2023","unstructured":"Kiyozuka, K. et al. M supports S1P production and conservation and mediates prolonged Akt activation via S1PR1 and S1PR3. J. Biochem. 174 (3), 253\u2013266 (2023).","journal-title":"J. Biochem."},{"issue":"11","key":"38157_CR39","doi-asserted-by":"publisher","first-page":"107837","DOI":"10.1016\/j.jbc.2024.107837","volume":"300","author":"Q Jones","year":"2024","unstructured":"Jones, Q. et al. Effect of phospholipid transfer protein on plasma sphingosine-1-phosphate. J. Biol. Chem. 300 (11), 107837 (2024).","journal-title":"J. Biol. Chem."},{"issue":"2","key":"38157_CR40","doi-asserted-by":"publisher","first-page":"R60","DOI":"10.1186\/cc11305","volume":"16","author":"SB Kumaraswamy","year":"2012","unstructured":"Kumaraswamy, S. B., Linder, A., Akesson, P. & Dahlback, B. Decreased plasma concentrations of Apolipoprotein M in sepsis and systemic inflammatory response syndromes. Crit. Care. 16 (2), R60 (2012).","journal-title":"Crit. Care"},{"issue":"3","key":"38157_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/cc11320","volume":"16","author":"C Christoffersen","year":"2012","unstructured":"Christoffersen, C. & Nielsen, L. B. Apolipoprotein M - a new biomarker in sepsis. Crit. Care. 16 (3), 126 (2012).","journal-title":"Crit. Care"},{"key":"38157_CR42","doi-asserted-by":"crossref","unstructured":"Swendeman, S. L. et al. An engineered S1P chaperone attenuates hypertension and ischemic injury. Sci. Signal. 10 (492). (2017).","DOI":"10.1126\/scisignal.aal2722"},{"issue":"1","key":"38157_CR43","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1096\/fj.201801245R","volume":"33","author":"P Keul","year":"2019","unstructured":"Keul, P. et al. Potent anti-inflammatory properties of HDL in vascular smooth muscle cells mediated by HDL-S1P and their impairment in coronary artery disease due to lower HDL-S1P: a new aspect of HDL dysfunction and its therapy. FASEB J. 33 (1), 1482\u20131495 (2019).","journal-title":"FASEB J."},{"issue":"7560","key":"38157_CR44","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nature14462","volume":"523","author":"VA Blaho","year":"2015","unstructured":"Blaho, V. A. et al. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature 523 (7560), 342\u2013346 (2015).","journal-title":"Nature"},{"issue":"1","key":"38157_CR45","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/cc11907","volume":"17","author":"JS Rachoin","year":"2013","unstructured":"Rachoin, J. S., Cerceo, E. & Dellinger, R. P. A new role for Statins in sepsis. Crit. Care. 17 (1), 105 (2013).","journal-title":"Crit. Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38157-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:41:34Z","timestamp":1781631694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38157-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38157"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38157-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MSW received funding by GRIFOLS (Barcelona, Spanien) and was awarded with the ALBUS award 2021 for this study. MSW received unrestricted funding from SARTORIUS (G\u00f6ttingen, Germany), the German Research Foundation (DFG, Bonn, Germany) and material support from Sphingotec (Berlin, Germany). MSW is in the advisory board of Gilead Science (Munich, Germany) and Amomed (Vienna, Austria). OM is a member of the Coordinating Guideline Committee (German S3 Guideline Invasive Ventilation and Extracorporeal Membrane Oxygenation in Acute Respiratory Insufficiency), Coordinating Committee (German guideline on prolonged weaning from mechanical ventilation). Within the last 36 months he received honoraria for lectures on coagulation from CSL Behring, holds a research grant provided by Advitos for conducting experimental studies on multiorgan failure and received funding from the German Research Foundation (DFG, Bonn, Germany) and the Federal Ministry of Education and Research; he received funding from Springer Publishing. All other authors do not declare any conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5412"}}